Dataset Information


No direct effect of SGLT2 activity on glucagon secretion.

ABSTRACT: AIMS/HYPOTHESIS:Sodium-glucose cotransporter (SGLT) 2 inhibitors constitute a new class of glucose-lowering drugs, but they increase glucagon secretion, which may counteract their glucose-lowering effect. Previous studies using static incubation of isolated human islets or the glucagon-secreting cell line ?-TC1 suggested that this results from direct inhibition of alpha cell SGLT1/2-activity. The aim of this study was to test whether the effects of SGLT2 on glucagon secretion demonstrated in vitro could be reproduced in a more physiological setting. METHODS:We explored the effect of SGLT2 activity on glucagon secretion using isolated perfused rat pancreas, a physiological model for glucagon secretion. Furthermore, we investigated Slc5a2 (the gene encoding SGLT2) expression in rat islets as well as in mouse and human islets and in mouse and human alpha, beta and delta cells to test for potential inter-species variations. SGLT2 protein content was also investigated in mouse, rat and human islets. RESULTS:Glucagon output decreased three- to fivefold within minutes of shifting from low (3.5 mmol/l) to high (10 mmol/l) glucose (4.0?±?0.5 pmol/15 min vs 1.3?±?0.3 pmol/15 min, p?


PROVIDER: S-EPMC7212061 | BioStudies | 2019-01-01

REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC6323192 | BioStudies
2020-01-01 | S-EPMC7554656 | BioStudies
2018-01-01 | S-EPMC6124499 | BioStudies
2017-01-01 | S-EPMC5544478 | BioStudies
2017-01-01 | S-EPMC5417681 | BioStudies
1000-01-01 | S-EPMC4989223 | BioStudies
1000-01-01 | S-EPMC6026318 | BioStudies
2019-01-01 | S-EPMC6778556 | BioStudies
2018-01-01 | S-EPMC6031905 | BioStudies
2015-01-01 | S-EPMC5886707 | BioStudies